Phase III FINEARTS-HF cardiovascular outcomes study of finerenone meets primary endpoint : Bayer

Bayer’s phase III FINEARTS-HF study has met its primary endpoint, demonstrating that finerenone significantly reduces cardiovascular death and heart failure (HF) events in patients with HF and a left ventricular ejection fraction (LVEF) of 40% or higher. Finerenone, known as Kerendia, was effective and well-tolerated, aligning with its established safety profile.

Heart failure affects over 60 million people globally, with many having a LVEF of 40% or less, which complicates management due to frequent comorbidities. Finerenone, a selective mineralocorticoid receptor antagonist, targets heart failure's underlying fibrosis.

The study involved around 6,000 patients and is part of Bayer's extensive MOONRAKER program, which includes multiple trials to understand finerenone’s effects on heart failure and chronic kidney disease.